CA3152021A1 - Substituted (7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino compounds useful as jak1 inhibitors - Google Patents
Substituted (7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino compounds useful as jak1 inhibitors Download PDFInfo
- Publication number
- CA3152021A1 CA3152021A1 CA3152021A CA3152021A CA3152021A1 CA 3152021 A1 CA3152021 A1 CA 3152021A1 CA 3152021 A CA3152021 A CA 3152021A CA 3152021 A CA3152021 A CA 3152021A CA 3152021 A1 CA3152021 A1 CA 3152021A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- salt
- formula
- jak1
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891706P | 2019-08-26 | 2019-08-26 | |
| US62/891,706 | 2019-08-26 | ||
| PCT/US2020/047767 WO2021041392A1 (en) | 2019-08-26 | 2020-08-25 | Substituted (7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino compounds useful as jak1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3152021A1 true CA3152021A1 (en) | 2021-03-04 |
Family
ID=74685810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3152021A Pending CA3152021A1 (en) | 2019-08-26 | 2020-08-25 | Substituted (7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino compounds useful as jak1 inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12492204B2 (https=) |
| EP (1) | EP4021452B1 (https=) |
| JP (1) | JP7671738B2 (https=) |
| CN (1) | CN114761011B (https=) |
| AU (1) | AU2020338043B2 (https=) |
| CA (1) | CA3152021A1 (https=) |
| ES (1) | ES2974946T3 (https=) |
| PL (1) | PL4021452T3 (https=) |
| WO (1) | WO2021041392A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020338043B2 (en) * | 2019-08-26 | 2025-12-18 | Chemwerth, Inc. | Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101667822B1 (ko) * | 2008-04-30 | 2016-10-19 | 내셔날 헬스 리서치 인스티튜트 | 오로라 키나아제 저해제용 접합 2고리 피리미딘 화합물 |
| CA2776028C (en) | 2009-10-15 | 2015-12-01 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| KR102032934B1 (ko) * | 2011-12-21 | 2019-10-16 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피롤 6원 헤테로아릴 고리 유도체, 그의 제조 방법, 및 그의 의약 용도 |
| US9926327B2 (en) | 2016-02-16 | 2018-03-27 | Zoetis Services Llc | Process for preparing 7H-pyrrolo[2,3-D]pyrimidine compounds |
| JP6944496B2 (ja) | 2018-10-22 | 2021-10-06 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体 |
| AU2020338043B2 (en) * | 2019-08-26 | 2025-12-18 | Chemwerth, Inc. | Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors |
-
2020
- 2020-08-25 AU AU2020338043A patent/AU2020338043B2/en active Active
- 2020-08-25 CN CN202080074639.8A patent/CN114761011B/zh active Active
- 2020-08-25 PL PL20858240.3T patent/PL4021452T3/pl unknown
- 2020-08-25 CA CA3152021A patent/CA3152021A1/en active Pending
- 2020-08-25 JP JP2022513571A patent/JP7671738B2/ja active Active
- 2020-08-25 EP EP20858240.3A patent/EP4021452B1/en active Active
- 2020-08-25 ES ES20858240T patent/ES2974946T3/es active Active
- 2020-08-25 US US17/638,074 patent/US12492204B2/en active Active
- 2020-08-25 WO PCT/US2020/047767 patent/WO2021041392A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PL4021452T3 (pl) | 2024-05-06 |
| AU2020338043A1 (en) | 2022-03-31 |
| US20220274992A1 (en) | 2022-09-01 |
| US12492204B2 (en) | 2025-12-09 |
| JP7671738B2 (ja) | 2025-05-02 |
| AU2020338043B2 (en) | 2025-12-18 |
| WO2021041392A1 (en) | 2021-03-04 |
| JP2022545836A (ja) | 2022-10-31 |
| ES2974946T3 (es) | 2024-07-02 |
| CN114761011A (zh) | 2022-07-15 |
| EP4021452A1 (en) | 2022-07-06 |
| CN114761011B (zh) | 2024-06-14 |
| EP4021452A4 (en) | 2023-01-04 |
| EP4021452B1 (en) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12398141B2 (en) | JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine | |
| US8372854B2 (en) | Pyrrolo[2,3-D]pyrimidine compounds | |
| US20230118795A1 (en) | Aryl or heteroaryl pyridone or pyrimidine derivative, preparation method and use thereof | |
| US20230167114A1 (en) | Macrocyclic jak inhibitor and use thereof | |
| US8841287B2 (en) | Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor | |
| JP2023508772A (ja) | Ｊａｋ阻害剤化合物及びその使用 | |
| CN113372351A (zh) | 一类jak激酶抑制剂及其制备和应用 | |
| WO2018133875A1 (zh) | Jak酶抑制剂及其制备方法和用途 | |
| JP2025501553A (ja) | 二環式インダゾールグルココルチコイド受容体拮抗薬 | |
| WO2021237121A1 (en) | Substituted pyridines | |
| AU2020338043B2 (en) | Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors | |
| JP7522414B2 (ja) | Ｊａｋキナーゼ阻害剤、その調製および適用 | |
| CA3144420A1 (en) | Bridged heterocyclyl-substituted pyrimidine compound, preparation method therefor, and pharmaceutical use thereof | |
| EP4011880A1 (en) | Jak kinase inhibitor and use thereof | |
| HK40077311B (en) | Substituted (7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino compounds useful as jak1 inhibitors | |
| HK40077311A (en) | Substituted (7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino compounds useful as jak1 inhibitors | |
| CN118742552A (zh) | 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途 | |
| WO2023064223A1 (en) | Tri-substituted pyridines | |
| KR20230141787A (ko) | 피라졸아미드 유도체 | |
| CN116063325A (zh) | 具有btk调节作用的大环化合物及其用途 | |
| WO2020035557A1 (en) | Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220920 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240805 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240805 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240805 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20241120 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250404 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250404 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250721 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250721 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED Effective date: 20251113 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251113 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT Effective date: 20251120 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251120 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251120 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251120 |